- Send a position-numbered sequence with the exact N- and C-terminal groups, stereochemistry and any cyclization or disulfide connectivity.
- Agree on the supplied form, quantity basis and analytical acceptance criteria before a synthesis quote is accepted.
- An intact mass check supports composition, but a complex modification may need sequence- or connectivity-specific evidence.
- A change to a terminal group or bridge pattern creates a different specification, even if the unmodified amino-acid string is unchanged.
What information belongs in a modified peptide RFQ?
Start with the complete amino-acid sequence, written from N terminus to C terminus. Number each residue and identify D-amino acids, noncanonical residues, linkers and attachment positions explicitly. Then state whether the N terminus is free or acetylated, whether the C terminus is an acid or amide, and whether the product is linear, backbone-cyclized or side-chain-cyclized. A supplier cannot infer these choices from the project name. C-terminal modification changes the molecule's physical and analytical behavior [1].
For a peptide containing several cysteines, name the intended disulfide pairs by residue number. A formula and molecular mass alone may fit more than one connectivity pattern. Include the desired salt or counter-ion, target delivered quantity, intended laboratory or cosmetic-research context, packaging form and acceptable testing package. The quotation can then identify a single defined material.
- Position-numbered sequence and stereochemistry
- Exact terminal groups and modification sites
- Cyclization chemistry or disulfide pairing
- Salt form, delivered quantity basis and agreed release tests
How do terminal caps and bridges change the analytical question?
A measured intact mass is a useful first check against the calculated composition, provided the report states the ion assignment and expected mass for the specified form. It does not automatically establish where a modification sits. N-terminal acetylation and C-terminal amidation should be evaluated against the agreed structure; a cysteine-rich peptide needs evidence that addresses the intended bridge pattern. Published cyclotide work describes why forming the correct disulfides is a distinct synthesis challenge [2].
Ask the laboratory what each proposed method resolves. HPLC can show separated peaks under a stated method, while MS or MS/MS can add structural information. Orthogonal methods may be appropriate when one test cannot distinguish plausible isomers or closely related impurities. ICH Q2(R2) frames this as specificity and selectivity within its regulated-product scope [3]; for a research-only order, use the same question without suggesting the material has an API release claim.
A useful identity package
Request the calculated and observed mass, the method used for chromatographic purity, and a stated plan for any positional or bridge isomer that matters to the project. Where connectivity is decisive, agree on a suitable mapping or comparative method before production. An ambiguous chromatogram is a poor time to choose the test.
- Calculated versus observed mass
- HPLC method and chromatogram linked to the lot
- Modification-site or bridge evidence when required
- Defined impurity-reporting and acceptance rules
Which decisions affect lead time and comparability?
Protecting-group strategy, resin selection, coupling behavior, oxidation or cyclization yield and purification burden can all change the work required for a modified sequence. The exact impact is sequence-specific, so a calendar estimate should name its assumptions and separate synthesis, purification, analysis and packaging. A repeat order should preserve the approved structure and test definitions; an alternate bridge-formation route or terminal chemistry needs a documented comparison before it is treated as equivalent.
Keep a controlled specification version with the inquiry, sample and production lot. If the buyer changes a linker, residue stereochemistry or terminal group after a pilot, request a new calculated mass, revised analytical plan and a fresh sample decision. ICH Q11 links material attributes and process parameters to quality attributes in drug-substance development [4]. Its framework is useful for asking what changed, while applicability to any PeptideSum item must be established separately.
- Version the sequence and modification map
- Separate sample approval from repeat-lot approval
- Record changed process steps and analytical comparability
- Confirm whether a new reference sample is needed
This article is for laboratory, analytical, procurement and qualified cosmetic-science contexts. It is not medical advice and does not provide dosing, administration or personal-use instructions.
Frequently asked questions
Is N-terminal acetylation the same product as a free N terminus?+
No. The terminal group changes the defined molecular structure. Put the N-terminal state in the sequence specification, expected mass and release documentation.
Can MS alone confirm a peptide's disulfide pattern?+
An intact mass can support the expected composition but may not distinguish different disulfide connectivities with the same composition. Agree on connectivity-sensitive evidence if the pairing matters.
Should a custom peptide quote include the salt form?+
Yes. The counter-ion or salt form affects how the material is described and may affect mass-balance and formulation decisions. Ask for the form and its analytical basis in the quotation.
Does this guide establish pharmaceutical-grade suitability?+
No. It is a specification and analytical-planning guide. Regulatory grade and release requirements depend on the actual product, manufacturer and intended use.